NewEdge Advisors’s Gossamer Bio GOSS Stock Holding History

NewEdge Advisors’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-145	Closed	-$315	–	3718
2022 Q4	$315	Buy	+145	New	+$1.19K	﹤0.01%	3247

Other funds holding GOSS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NewEdge Advisors's GOSS Position: Q1 2023 in Review

NewEdge Advisors sold out of Gossamer Bio (GOSS) in Q1 2023, closing a stake of 145 shares — an estimated $315 sold.

NewEdge Advisors first reported a position in GOSS in Q4 2022 and held it in 1 quarter. The position peaked at $315 in Q4 2022. 111 funds tracked by Wall St. Rank hold GOSS as of Q1 2023.

NewEdge Advisors reported no remaining Gossamer Bio position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 145 Gossamer Bio shares in Q1 2023, an estimated $315.
NewEdge Advisors first reported a position in Gossamer Bio in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Gossamer Bio position peaked at $315 in Q4 2022.
111 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.